ACHE and myasthenia gravis: Furthermore, the bioactivity evaluation assay showed that kadsuricoccins A and B have moderate AChE inhibitory activities with predicted lower toxicity as some pentacyclic triterpenoids [17], while the AChE was an important target for Alzheimer’s Disease (AD) [18] and myasthenia gravis [19].